Jobevne Becomes Seventh Biosimilar Approved in the U.S. by Biocon Subsidiary
Biocon Biologics Ltd., a subsidiary of Indian biopharmaceutical major Biocon Ltd., has announced that it has received approval from the U.S. Food and Drug Administration (U.S. FDA) for its monoclonal antibody biosimilar, Jobevne. The approval marks a critical advancement in the company’s oncology pipeline and further consolidates Biocon’s strategic footprint in the regulated U.S. biosimilars market. According to the company’s exchange filing, Jobevne is a humanized monoclonal antibody used in the treatment of multiple cancer types, making it a high-value asset in Biocon’s therapeutic portfolio.
The U.S. FDA’s approval of Jobevne represents Biocon Biologics’ seventh biosimilar to be greenlit in the U.S., underscoring the company’s continued success in biologics innovation and regulatory execution. The product joins a growing list of Biocon-approved biosimilars in the U.S., which includes OGIVRI (trastuzumab) and FULPHILA (pegfilgrastim). These approvals are a result of Biocon Biologics’ focused investments in biologics R&D, regulatory compliance, and global partnerships.
Highlights:
Jobevne is a monoclonal antibody indicated for cancer treatment.
Approved by the U.S. FDA, adding to Biocon’s robust biosimilar portfolio.
Seventh biosimilar from Biocon Biologics to be approved in the U.S.
Enhances company’s position in the U.S. oncology biologics segment.
Global Expansion Strategy Continues With Market Presence in Europe and Canada
The latest U.S. FDA nod follows Jobevne’s prior approvals in other regulated markets, showcasing the company’s expanding international presence in biosimilars. In Europe, the same molecule is marketed under the brand name ABEVMY, which received regulatory clearance from the European Medicines Agency (EMA) in February 2021. In November 2021, Health Canada approved ABEVMY, allowing Biocon Biologics to distribute its bevacizumab biosimilar across North America and Europe. The drug is used as a cost-effective alternative to the reference biologic Avastin® and plays a crucial role in cancer care, particularly in regions facing cost constraints in healthcare access.
With Jobevne now approved in the U.S., the company is poised to capture a larger share of the oncology biosimilars market. Biocon Biologics’ strategy centers on leveraging regulatory approvals across multiple jurisdictions to drive affordability and accessibility for patients requiring complex biologics therapies. The expansion is also key to Biocon’s broader vision of becoming a global leader in the biosimilars space by establishing a robust product pipeline, high-volume manufacturing capacity, and strong marketing alliances.
Highlights:
Jobevne approved as ABEVMY in Europe (Feb 2021) and Canada (Nov 2021).
Targets cost-effective cancer treatment in developed markets.
Aligned with Biocon’s strategy to penetrate global biosimilar markets.
Strengthens access to oncology treatments across regulatory zones.
Leadership Statement Reinforces Long-Term Growth Vision
Commenting on the regulatory approval, Shreehas Tambe, CEO & Managing Director of Biocon Biologics Ltd., said: “The U.S. FDA approval is a significant milestone—our seventh biosimilar approved in the U.S. and a strong addition to our robust oncology portfolio. It underscores the depth of our scientific expertise and commitment to expanding access to high-quality, affordable biologics.” Tambe emphasized that Jobevne’s inclusion in Biocon’s portfolio not only supports the company’s mission of biosimilar leadership but also highlights the scalability of its development and regulatory infrastructure.
The company views biosimilars as a vital component of future pharmaceutical growth, particularly in markets like the United States where biologics constitute a major share of prescription drug spending. With biosimilar adoption steadily increasing in the U.S., Biocon Biologics expects to leverage its FDA-approved pipeline to drive volume-based growth and increase market penetration.
Highlights:
CEO calls Jobevne approval a strategic milestone.
Reinforces Biocon’s mission to provide affordable oncology therapies.
Signals company readiness to scale operations in U.S. market.
Positions Biocon Biologics for long-term biosimilar market leadership.
Market Response and Share Price Performance
Despite the significant regulatory development, shares of Biocon Ltd. closed over 5% lower at ₹305.6 on the National Stock Exchange (NSE) during Wednesday’s trade. The decline was attributed to broader market volatility and investor profit-booking, rather than any company-specific negative sentiment. Analysts expect sentiment around Biocon Biologics to improve over the medium term as Jobevne’s commercial launch gains traction in the U.S. and revenue streams from oncology biosimilars begin to contribute meaningfully to the company’s financials.
Market experts also noted that with multiple biosimilar launches in highly competitive categories, commercial execution and payer access strategies will be key determinants of success. Biocon Biologics has partnered with major global pharmaceutical distributors in the past to enhance product uptake and reach, which could potentially support Jobevne’s performance in the U.S. oncology segment.
Highlights:
Biocon stock closed 5% lower at ₹305.6 despite positive news.
Broader market sentiment influenced intraday movement.
Investors likely to watch for commercial rollout and revenue impact.
Competitive execution will be critical to Jobevne’s market success.
